Polymeric nanoparticle-conjugated camptothecin DAN-222
Term · Oncology and biomedicine · MLC-T-ONC-016165
A polymeric nanoparticle formulation of the topoisomerase I inhibitor camptothecin (CPT), an alkaloid isolated from the Chinese tree Camptotheca acuminata, covalently conjugated, via a linker, to a biocompatible polymer scaffold, with potential antineoplastic activity. Upon intravenous administration of polymeric nanoparticle-conjugated CPT DAN-222, the nanoparticles accumulate in tumor tissue and CPT is released from the formulation at the tumor site and taken up by tumor cells. During the S phase of the cell cycle, CPT selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Compared to CPT alone, the nanoparticle formulation has a prolonged half-life and greatly improves the biodistribution of CPT resulting in an accumulation of CPT at the tumor site, which enhances tumor exposure while greatly reducing toxic side effects.
| Identifier | MLC-T-ONC-016165 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | polymeric nanoparticles DAN-222; polymeric nanoparticle-containing camptothecin DAN-222 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016165",
"term": "Polymeric nanoparticle-conjugated camptothecin DAN-222",
"field": "Oncology and biomedicine",
"definition": "A polymeric nanoparticle formulation of the topoisomerase I inhibitor camptothecin (CPT), an alkaloid isolated from the Chinese tree Camptotheca acuminata, covalently conjugated, via a linker, to a biocompatible polymer scaffold, with potential antineoplastic activity. Upon intravenous administration of polymeric nanoparticle-conjugated CPT DAN-222, the nanoparticles accumulate in tumor tissue and CPT is released from the formulation at the tumor site and taken up by tumor cells. During the S phase of the cell cycle, CPT selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Compared to CPT alone, the nanoparticle formulation has a prolonged half-life and greatly improves the biodistribution of CPT resulting in an accumulation of CPT at the tumor site, which enhances tumor exposure while greatly reducing toxic side effects.",
"synonyms": [
"polymeric nanoparticles DAN-222",
"polymeric nanoparticle-containing camptothecin DAN-222"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/polymeric-nanoparticle-conjugated-camptothecin-dan-222/"
}
Record 13,452 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.